A client with chronic kidney disease has received epoetin alfa for 4 weeks. Which finding best supports that the therapy is effective?
1Hemoglobin rises from 8.2 to 9.4 g/dL, and the client reports less fatigue✓ Correct answer
2Blood pressure rises from 128/76 to 168/94 mm Hg after treatment begins
3Hemoglobin reaches 12.6 g/dL, and the dose continues without reassessment at the next visit
4Serum potassium falls from 5.1 to 3.4 mEq/L after another weekly dose
Explanation
Epoetin alfa stimulates red blood cell production to reduce anemia and transfusion needs. A gradual hemoglobin rise with improved fatigue supports effectiveness, while hypertension or an excessive hemoglobin target increases harm.
Quick answer A gradual hemoglobin increase with less fatigue indicates the intended epoetin alfa response.
Why this is correct Chronic kidney disease can reduce endogenous erythropoietin and red-cell production. Epoetin alfa should produce a monitored rise in hemoglobin and improve anemia-related symptoms while the dose is adjusted to avoid rapid or excessive elevation.
Easy analogy or mental picture Epoetin is like increasing a factory's red-cell production at a controlled rate. The analogy explains the gradual response but does not set a universal hemoglobin target or replace dose-specific monitoring.
Memory hook Epoetin success is gradual hemoglobin recovery with fewer anemia symptoms.
NCLEX decision rule Judge an erythropoiesis-stimulating agent by controlled hematologic improvement, not by unrelated electrolyte change. Treat hypertension or an excessive hemoglobin rise as a safety concern requiring reassessment.
Why the other choices are wrong Marked hypertension is an adverse effect. A high hemoglobin without dose review increases cardiovascular risk, and epoetin is not intended to lower potassium.
References
[1]
NCSBN: 2026 NCLEX-RN Test PlanNational Council of State Boards of Nursing
[2]
DailyMed: Epogen Prescribing InformationU.S. National Library of Medicine, updated July 2026